Cell Reports (May 2018)

Site-Specific Gene Editing of Human Hematopoietic Stem Cells for X-Linked Hyper-IgM Syndrome

  • Caroline Y. Kuo,
  • Joseph D. Long,
  • Beatriz Campo-Fernandez,
  • Satiro de Oliveira,
  • Aaron R. Cooper,
  • Zulema Romero,
  • Megan D. Hoban,
  • Alok V. Joglekar,
  • Georgia R. Lill,
  • Michael L. Kaufman,
  • Sorel Fitz-Gibbon,
  • Xiaoyan Wang,
  • Roger P. Hollis,
  • Donald B. Kohn

DOI
https://doi.org/10.1016/j.celrep.2018.04.103
Journal volume & issue
Vol. 23, no. 9
pp. 2606 – 2616

Abstract

Read online

X-linked hyper-immunoglobulin M (hyper-IgM) syndrome (XHIM) is a primary immunodeficiency due to mutations in CD40 ligand that affect immunoglobulin class-switch recombination and somatic hypermutation. The disease is amenable to gene therapy using retroviral vectors, but dysregulated gene expression results in abnormal lymphoproliferation in mouse models, highlighting the need for alternative strategies. Here, we demonstrate the ability of both the transcription activator-like effector nuclease (TALEN) and clustered regularly interspaced short palindromic repeats-associated protein 9 (CRISPR/Cas9) platforms to efficiently drive integration of a normal copy of the CD40L cDNA delivered by Adeno-Associated Virus. Site-specific insertion of the donor sequence downstream of the endogenous CD40L promoter maintained physiologic expression of CD40L while overriding all reported downstream mutations. High levels of gene modification were achieved in primary human hematopoietic stem cells (HSCs), as well as in cell lines and XHIM-patient-derived T cells. Notably, gene-corrected HSCs engrafted in immunodeficient mice at clinically relevant frequencies. These studies provide the foundation for a permanent curative therapy in XHIM.

Keywords